Passage BIO, Inc. (PASG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Passage BIO, Inc. on August 2, 2024, regarding an event that occurred on August 1, 2024. The Company is an emerging growth company incorporated in Delaware, with its common stock listed on the Nasdaq Global Select Market under the symbol "PASG."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the trading price of the Company's common stock, which has fallen below $1.00 per share for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a Notice from the Nasdaq Listing Qualifications staff indicating non-compliance with Nasdaq Listing Rule 5450(a)(1) due to the minimum bid price requirement. The Company's stock price has remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial compliance period of 180 calendar days, ending January 28, 2025, to regain compliance.
- Requirements to Cure: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to January 28, 2025.
- Alternative Options: If compliance is not met by the deadline, the Company may be eligible for an additional 180-day grace period if it applies to transfer its listing to the Nasdaq Capital Market. This would require meeting market value and other initial listing standards, potentially necessitating a reverse stock split.
- Risks: There is no assurance the Company will regain compliance. Failure to do so could result in delisting. The Company retains the right to appeal a delisting determination.
- Management Action: The Company is considering actions to regain compliance but has not made any decisions at this time.
Investor Verification Checklist
- Verify the current closing bid price of PASG stock to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor future filings for announcements regarding a potential reverse stock split or transfer to the Nasdaq Capital Market.
- Review the Company's cash position in recent 10-Q or 10-K filings to determine if liquidity constraints impact the ability to execute capital structure changes.
- Check for any subsequent 8-K filings regarding the status of the compliance period or appeals.